General Information of Drug (ID: DM4ZN8M)

Drug Name
N-803 Drug Info
Synonyms Anktiva; ALT-803
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM4ZN8M

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Interleukin-15 (IL15)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BNZ-1 DM8JQZC Cutaneous T-cell lymphoma 2B01 Phase 2 [3]
AMG-714 DM1T3KQ Coeliac disease DA95 Phase 2 [4]
SAR445877 DM91KZL Aggressive cancer 2A00-2F9Z Phase 2 [5]
PF-07209960 DM1W90B Aggressive cancer 2A00-2F9Z Phase 1 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-15 (IL15) TTJFA35 IL15_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT04808908) Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease. U.S. National Institutes of Health.
2 The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PLoS Pathog. 2020 Mar 12;16(3):e1008339.
3 Clinical pipeline report, company report or official report of Bioniz Therapeutics.
4 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
5 Clinical pipeline report, company report or official report of Sanofi
6 ClinicalTrials.gov (NCT04628780) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.